艾昆纬-Mounjaro：预防保健和消费者健康的新时代（英）-2023-10页_442kb

Mounjaro: Unprecedented Market Success in Diabetes and Obesity Care

Sales Performance Outcomes

Mounjaro, approved for type 2 diabetes in 2022, has demonstrated extraordinary market performance with sales exceeding other GLP-1 drugs like Bydureon by a factor of 10 in month 10, and cumulative sales more than doubling the rest of the market combined in its first year. This trajectory, uncommon for non-curative diabetes drugs, resembles historical leaders like Harvoni or Lipitor, indicating a unique market influence. Shortages related to high demand for Semaglutide products like Ozempic and Wegovy contributed to Mounjaro's uptake, with providers transitioning patients to it, despite supply challenges.

Reasons for Success and Market Impact

Mounjaro's efficacy not only addresses diabetes but also shows strong potential in weight loss, with an estimated 20-25% of its use off-label for obesity. This positions it as a key player in preventive care, highlighting obesity's role in comorbidities and its significant year-round cost in the U.S. ($173 billion), making stakeholders reconsider obesity not just as a cosmetic issue but as a critical health risk. Mounjaro's patient demographics fall between Ozempic and Wegovy profiles, often involving individuals over 40 who may be seeking preventive measures against other diseases, emphasizing a shift in clinical decision-making.

Shift Trends in Healthcare

The rise in patient behavior includes increased use of telemedicine and online pharmacies for accessing GLP-1 drugs, reflecting a consumer-led approach to healthcare. Patients are willing to pay out-of-pocket despite insurance changes, indicating a move towards proactive health management through these channels. This trend suggests healthcare must adapt to patient preferences and consumer-grade experiences to maintain loyalty and mitigate risks, signaling a new era where preventive care blends medical and consumer-focused elements.

Future Implications for Preventive Care

Mounjaro's performance underscores that preventive care is highly valued and capable of substantial returns, moving beyond traditional models. It encourages manufacturers and payers to align with patient-centric strategies, integrate care settings beyond doctor's offices, and prioritize holistic prevention to foster healthier outcomes and economic benefits across the healthcare system.